Patents by Inventor Yiannis Ioannou

Yiannis Ioannou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180044286
    Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 15, 2018
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, and Human Services
    Inventors: Samarjit PATNAIK, Mercedes TAYLOR, Raul Rolando CALVO, Juan Jose MARUGAN, Noel SOUTHALL, Wei ZHENG, Marc FERRER-ALEGRE, Seameen DEHDASTHI, Patricia DRANCHAK, Fannie CHEN, Yiannis IOANNOU
  • Patent number: 9724328
    Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: August 8, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Neurotrope Bioscience
    Inventors: Yiannis A. Ioannou, Lawrence Altstiel, David R. Crockford, Sathapana Kongsamut
  • Publication number: 20170172978
    Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a pharmaceutically effective amount of bryostatin 1.
    Type: Application
    Filed: April 14, 2015
    Publication date: June 22, 2017
    Inventors: Yiannis A. IOANNOU, Lawrence ALTSTIEL, David R. CROCKFORD, Sathapana KONGSAMUT
  • Publication number: 20150297559
    Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.
    Type: Application
    Filed: April 14, 2015
    Publication date: October 22, 2015
    Inventors: Yiannis A. IOANNOU, Lawrence Altstiel, David R. CROCKFORD, Sathapana KONGSAMUT
  • Publication number: 20100119525
    Abstract: The present invention relates to a method for prolonging longevity using and NPC1L1 antagonist. The present invention also provides a method for reducing weight in an individual who consumes a high-fat diet using an NPC1L1 antagonist.
    Type: Application
    Filed: August 1, 2006
    Publication date: May 13, 2010
    Applicant: MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITY
    Inventor: Yiannis Ioannou
  • Publication number: 20090035784
    Abstract: The present invention provides a novel gene, designated herein as “NPC1L1”, that is associated with lipid or glucose metabolism. The invention further provides the use of the NPC1L1 gene and its corresponding protein to diagnose a lipid condition in a cell or tissue and to screen for novel therapeutic compounds useful for treating lipid disorders and other NPC1L1-associated or mediated diseases or disorders. The invention further provides specific inhibitors of NPC1L1.
    Type: Application
    Filed: August 1, 2005
    Publication date: February 5, 2009
    Applicant: Mount Sinai School of Medicine of New York University
    Inventors: Yiannis Ioannou, Joanna P. Davies
  • Patent number: 6455037
    Abstract: The present invention relates to methods and compositions for the reduction of xenotransplantation rejection. Specifically, the present invention relates, first, to transgenic cells, tissues, organs and animals containing transgenic nucleic acid molecules that direct the expression of gene products, including, but not limited to enzymes, capable of modifying, either directly or indirectly, cell surface carbohydrate epitopes such that the carbohydrate epitopes are no longer recognized by natural human antibodies or by the human cell-mediated immune response, thereby reducing the human immune system response elicited by the presence of such carbohydrate epitopes. In a preferred embodiment, the transgenic cells, tissues, organs and animals express nucleic acid molecules encoding functional recombinant &agr;-Galactosidase A (&agr;GalA) enzyme which modifies the carbohydrate epitope Gal&agr;(1,3)Gal.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: September 24, 2002
    Assignees: Mount Sinai School of Medicine of the City University of New York, The Austin Research Institute
    Inventors: Yiannis Ioannou, Robert J. Desnick, Mauro S. Sandrin, Ian F. C. McKenzie
  • Patent number: 5580757
    Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used, but is not limited to, in the treatment in Fabry Disease; for the hydrolysis of .alpha.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: December 3, 1996
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou
  • Patent number: 5491075
    Abstract: The present invention involves the production of human .alpha.-GalNAc by cloning and expressing the .alpha.-GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced.The .alpha.-GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in various glycoconjugates.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: February 13, 1996
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou, Anne M. Wang
  • Patent number: 5401650
    Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used, but is not limited to, in the treatment in Fabry Disease; for the hydrolysis of .alpha.
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: March 28, 1995
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou
  • Patent number: 5382524
    Abstract: The present invention involves the production of human .alpha.-GalNAc by cloning and expressing the .alpha.-GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced.The .alpha.-GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in various glycoconjugates.
    Type: Grant
    Filed: October 24, 1990
    Date of Patent: January 17, 1995
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou, Anne M. Wang
  • Patent number: 5356804
    Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used in the treatment in Fabry Disease; for the hydrolysis of .alpha.
    Type: Grant
    Filed: October 24, 1990
    Date of Patent: October 18, 1994
    Assignee: Mount Sinai School of Medicine of the City of New York
    Inventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou